• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Waters Corporation

    6/20/24 3:57:49 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email
    11-K 1 d706723d11k.htm 11-K 11-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 11-K

     

     

     

    ☒

    ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the fiscal year ended December 31, 2023

    Or

     

    ☐

    TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from       to     

    Commission File Number: 01-14010

     

     

     

    A.

    Full title of the plan and the address of the plan, if different from that of the issuer name below:

    Waters Employee Investment Plan

     

    B.

    Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

    Waters Corporation

    34 Maple Street

    Milford, Massachusetts 01757

     

     

     


    Required Information

    Financial Statements and Supplemental Schedule

    Report of Independent Registered Public Accounting Firm

    Statements of Net Assets Available for Benefits as of December 31, 2023 and 2022

    Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2023

    Notes to Financial Statements

    Form 5500 – Schedule H, Part IV, Line 4i – Schedule of Assets (Held at End of Year) as of December 31, 2023

    Exhibit

     

    Designation

      

    Description

      

    Method of Filing

    Exhibit 23.1

       Consent of Grant Thornton LLP    Filed with this Report


    SIGNATURE

    The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Waters Employee Investment Plan
    Date: June 20, 2024     By:  

    /s/ Amol Chaubal

          Amol Chaubal
          Senior Vice President and Chief Financial Officer


    WATERS EMPLOYEE INVESTMENT PLAN

    FINANCIAL STATEMENTS

    AND

    SUPPLEMENTAL SCHEDULE

    AS OF DECEMBER 31, 2023 and 2022

    AND FOR THE YEAR ENDED DECEMBER 31, 2023

    WITH

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


    WATERS EMPLOYEE INVESTMENT PLAN

    INDEX TO FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULE

    as of December 31, 2023 and 2022

    and for the Year Ended December 31, 2023

     

         Page  

    Report of Independent Registered Public Accounting Firm

         1  

    Financial Statements:

      

    Statements of Net Assets Available for Benefits

         2  

    Statement of Changes in Net Assets Available for Benefits

         3  

    Notes to Financial Statements

         4  

    Supplemental Schedule *:

      

    Form 5500 – Schedule H, Part IV, Line 4i – Schedule of Assets (Held at End of Year) as of December 31, 2023

         9  

     

    *

    Other supplemental schedules required by Section 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 have been omitted because they are not applicable.


    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

    Employee Benefits Administration Committee, Plan Administrator, and Plan Participants

    Waters Employee Investment Plan

    Opinion on the financial statements

    We have audited the accompanying statements of net assets available for benefits of Waters Employee Investment Plan (the “Plan”) as of December 31, 2023 and 2022, the related statement of changes in net assets available for benefits for the year ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2023 and 2022, and the changes in net assets available for benefits for the year ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.

    Basis for opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental information

    The supplemental information in the accompanying Schedule H, Part IV, Line 4(i) – Schedule of Assets (Held at End of Year) as of December 31, 2023 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ GRANT THORNTON LLP

    We have served as the Plan’s auditor since 2006.

    Boston, Massachusetts

    June 20, 2024

     

    1


    WATERS EMPLOYEE INVESTMENT PLAN

    Statements of Net Assets Available for Benefits

    as of December 31, 2023 and 2022

     

         December 31,  
         2023      2022  

    Assets

         

    Investments, at fair value (Note 3)

       $ 1,125,279,892      $ 972,478,827  

    Notes receivable from participants

         7,863,313        7,774,126  

    Employer contributions receivable

         1,379,350        1,566,287  
      

     

     

        

     

     

     

    Net assets available for benefits

       $ 1,134,522,555      $ 981,819,240  
      

     

     

        

     

     

     

    See accompanying notes to the financial statements.

     

    2


    WATERS EMPLOYEE INVESTMENT PLAN

    Statement of Changes in Net Assets Available for Benefits

    for the Year Ended December 31, 2023

     

    Additions

      

    Net investment income:

      

    Net appreciation in fair value of investments

       $ 165,716,992  

    Interest income

         2,177,782  

    Dividend income

         9,110,499  
      

     

     

     

    Total investment income

         177,005,273  

    Interest income on notes receivable from participants

         396,008  

    Contributions:

      

    Employer’s contributions

         21,201,537  

    Employees’ contributions

         35,367,158  

    Rollovers

         9,408,138  
      

     

     

     

    Total contributions

         65,976,833  
      

     

     

     

    Other income

         69,962  

    Total additions

         243,448,076  

    Deductions

      

    Benefits paid directly to beneficiaries and participants

         109,629,207  

    Administrative expenses

         486,979  
      

     

     

     

    Total deductions

         110,116,186  
      

     

     

     

    Net increase before transfer of assets

         133,331,890  

    Transfer of assets into the Plan (see Note 1)

         19,371,425  

    Net assets available for benefits:

      

    Beginning of year

         981,819,240  
      

     

     

     

    End of year

       $ 1,134,522,555  
      

     

     

     

    See accompanying notes to the financial statements.

     

    3


    WATERS EMPLOYEE INVESTMENT PLAN

    Notes to Financial Statements

    December 31, 2023 and 2022

    1 Description of Plan

    The following description of the Waters Employee Investment Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

    General

    The Plan, effective August 19, 1994, was created to provide an opportunity for eligible employees of Waters Technologies Corporation (“Waters” or the “Company”) and any eligible legally affiliated company to provide for their future financial security through participation in a systematic savings program to which each participating employer (the “Employer”) also contributes. The Plan is a defined contribution plan covering substantially all employees of the Company and its affiliates who work in the United States. The Plan is designed to take advantage of provisions of the Internal Revenue Code of 1986, as amended (the “Code”), which allow a participant to elect to reduce taxable compensation (subject to certain limitations) with the amount of such reduction being contributed to the Plan by the Employer on behalf of the electing participant. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

    The Plan is a Safe Harbor Plan, which provides for catch-up contributions by participants who have attained age 50 before the close of the Plan year, to satisfy the alternative methods of meeting nondiscrimination requirements, and redefine employer matching contributions.

    Plan Mergers and Transfers

    The Company acquired Wyatt Technology, LLC in May 2023. The Wyatt 401(k) Plan (the “Wyatt Plan”) was merged, and the assets were transferred into the Plan. In connection with the merger, $19,371,425 of net assets were transferred into the Plan and are reflected as transfers of assets into the Plan in the Statement of Changes in Net Assets Available for Benefits for the year ended December 31, 2023.

    Eligibility

    Employees are eligible to participate and are automatically enrolled in the Plan immediately upon their date of hire or rehire. Unless the employee elects to suspend automatic contributions, the automatic participation will commence at 3% of annual compensation and increase 1% each year until contributions reach 6% of annual compensation.

    Contributions

    All participants may elect to make after-tax Roth 401(k) contributions through the Plan in addition to pretax contributions.

    Subject to certain limitations, participants may elect to voluntarily contribute to the Plan through payroll deductions from 1% to 60% of their annual compensation on a pretax basis and/or on an after-tax basis as a Roth 401(k) contribution. Participants who have attained age 50, or who will reach age 50 during the year, may elect to make an additional pretax contribution or Roth 401(k) contribution, or both, to the Plan of up to $7,500 for 2023, provided their regular pretax and Roth 401(k) contributions reach either the Plan’s limit of eligible earnings or the Internal Revenue Service (“IRS”) dollar limit of $22,500 for 2023. As of December 31, 2023, participants had various investment options in which to direct the investment of their contributions and Company contributions. Each investment option offers a different level of risk and expected rate of return. All contributions are subject to the limitations of the Code.

    For contribution purposes, compensation includes salary, lump sum cash payments of merit pay increases, commissions, overtime pay, shift differentials, short-term disability pay, unused vacation pay, bonuses paid under the performance bonus plan and annual incentive bonuses or certain other designated incentive plans. The Employer will match 100% of the first 6% of compensation contributed by the participant to the Plan on a combined pretax and Roth 401(k) basis. The Employer matching contribution is effective immediately upon date of eligibility and follows the investment elections selected by the participant for employee contributions. Contributions and compensation considered for matching contribution purposes are subject to certain limitations.

     

    4


    WATERS EMPLOYEE INVESTMENT PLAN

    Notes to Financial Statements

    December 31, 2023 and 2022

     

    Participants direct their elective contributions into various investment options offered by the Plan, which include a self-directed brokerage account feature and a Company stock fund, and can change their investments options on a daily basis.

    Participant Accounts

    Each participant’s account is credited with the participant’s contributions, any applicable Employer matching contributions and an allocation of Plan earnings, and is charged with an allocation of administrative expenses to the extent that they are paid by the Plan. Certain administrative expenses are charged directly against participants’ accounts. Allocations of earnings and expenses are based on the participant account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s account balance.

    Vesting

    Participants are immediately vested in their voluntary contributions as well as Employer matching contributions, plus actual earnings thereon.

    Rollover Election

    Employees may make an eligible rollover contribution to the Plan at any time.

    Administration

    Fidelity Management Trust Company (“Fidelity”) is the trustee and custodian for the Plan. Fidelity Investments Institutional Operations Company (“FIIOC”) is the record keeper for the Plan.

    Benefits

    Upon termination of service due to death, disability, retirement or other reason, a participant or beneficiary may elect to receive a lump-sum amount equal to the value of the participant’s vested interest in his or her account balance or annual or more frequent installments over a period not to extend beyond the life expectancy of the participant. The Plan also allows participants who are actively employed and have attained the age of 59 1/2 to withdraw all or any portion of their account balance for any reason. The Plan also provides for certain hardship withdrawals upon approval by the Plan administrator, a representative of the Company’s management.

    Administrative Expenses

    Certain administrative expenses, including loan maintenance, brokerage account fees, Waters Corporation Stock Fund (“Stock Fund”) administrative fees and in-service withdrawal fees, are paid by the participants. Other expenses, such as legal, audit and consulting fees, incurred in the administration of the Plan are paid by the Company. A portion of the operating expenses and management fees is returned to the Plan on revenue sharing arrangements. The revenue sharing amounts received are recorded as other income in the statement of changes in net assets available for benefits.

    Notes Receivable from Participants

    Participants in the Plan may borrow from their account balance, with a maximum of two loans permitted per participant. A participant may borrow an amount greater than or equal to $1,000 but not to exceed the lesser of (a) $50,000 minus the largest outstanding loan balance in the twelve months preceding the loan request or (b) 50% of the total account balance minus current outstanding loan balances. Principal and interest are repaid through payroll deductions for a period of up to five years, except for loans made for purchasing or constructing a principal residence for which the repayment term may be up to 20 years. The loans bear interest at a fixed rate equal to the prime rate on the first business day of the calendar quarter in which the loan is funded and are collateralized by the participant’s account balances. At December 31, 2023, interest rates on outstanding loans ranged from 3.25% to 8.50%.

    2 Summary of Significant Accounting Policies

    Basis of Accounting

    The financial statements of the Plan are prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Benefits payable at year end are not accrued as they are considered to be a component of net assets available for benefits.

     

    5


    WATERS EMPLOYEE INVESTMENT PLAN

    Notes to Financial Statements

    December 31, 2023 and 2022

     

    Investment Transactions and Investment Income

    The Plan’s investments are stated at fair value. Shares of common stock and mutual funds are valued at quoted market prices, which represent the net asset value of the shares held by the Plan at year end. Purchases and sales of securities are recorded on a trade-date basis. Dividends are recorded on the ex-dividend date. Interest income is recorded on the accrual basis as earned. 

    Waters Corporation common stock is traded on a national securities exchange and is valued at the last reported sales price on the last business day of the year. The common stock was valued at $329.23 and $342.58 per share at December 31, 2023 and 2022, respectively.

    The Plan presents in the statement of changes in net assets the net appreciation or depreciation in the fair value of its investments that consists of the realized gains or losses and unrealized appreciation or depreciation on those investments.

    Contributions

    Employer and participant contributions are recorded in the period in which payroll deductions are made from the participant’s compensation.

    Benefit Payments

    Benefit distributions are recorded when paid.

    Notes Receivable from Participants

    Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Interest income on notes receivable from participants is recorded when it is earned. Related fees are recorded as administrative expenses and are expensed when they are incurred. If a participant ceases to make loan repayments, the Plan administrator will deem the participant loan to be a distribution in accordance with applicable legal requirements, and the participant’s account balance will be reduced at the earliest permitted date as outlined in the Plan document.

    Use of Estimates

    The preparation of the Plan’s financial statements in conformity with U.S. GAAP requires the Plan administrator to make significant estimates and assumptions that affect the reported amounts of net assets available for benefits at the date of the financial statements and the changes in net assets available for benefits during the reporting period and, when applicable, disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.

    Risks and Uncertainties

    The Plan provides for various investment options in any combination of stocks, bonds, fixed income securities, mutual funds and other investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants’ account balances and the amounts reported in the statements of net assets available for benefits.

    3 Fair Value Measurements

    In accordance with the accounting standards for fair value measurements and disclosures, the Plan’s assets are measured at fair value on a recurring basis as of December 31, 2023 and 2022. Fair values determined by Level 1 inputs utilize observable data, such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize observable data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points for which there is little or no market data, which require the reporting entity to develop its own assumptions. If the Plan were to change its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it would need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Plan would recognize these transfers at the beginning of the reporting period in which the transfers occurred.

     

    6


    WATERS EMPLOYEE INVESTMENT PLAN

    Notes to Financial Statements

    December 31, 2023 and 2022

     

    During the years ended December 31, 2023 and 2022, there were no transfers of financial assets or financial liabilities between the hierarchy levels.

    The following table discloses the Plan’s assets measured at fair value on a recurring basis as of December 31, 2023:

     

         Total
    December 31, 2023
         Quoted Prices in
    Active Market for
    Identical Assets

    (Level 1)
         Significant Other
    Observable Inputs

    (Level 2)
         Significant
    Unobservable
    Inputs

    (Level 3)
     

    Waters Corporation Common Stock

       $ 70,668,232      $ 70,668,232      $ —       $  —   

    Interest-bearing cash

         1,942,963        1,942,963        —         —   

    Mutual funds

         382,842,675        382,842,675        —         —   

    Self-directed brokerage assets

         49,461,154        49,461,154        —         —   

    Common collective trusts

         620,364,868        —         620,364,868        —   
      

     

     

        

     

     

        

     

     

        

     

     

     

    Total assets in the fair value hierarchy

       $ 1,125,279,892      $ 504,915,024      $ 620,364,868      $ —   
      

     

     

        

     

     

        

     

     

        

     

     

     

    The following table discloses the Plan’s assets measured at fair value on a recurring basis as of December 31, 2022:

     

         Total
    December 31, 2022
         Quoted Prices in
    Active Market for
    Identical Assets

    (Level 1)
         Significant Other
    Observable Inputs

    (Level 2)
         Significant
    Unobservable
    Inputs

    (Level 3)
     

    Waters Corporation Common Stock

       $ 79,898,220      $ 79,898,220      $ —       $ —   

    Interest-bearing cash

         2,536,006        2,536,006        —         —   

    Mutual funds

         307,818,265        307,818,265        —         —   

    Self-directed brokerage assets

         45,291,949        45,291,949        —         —   

    Common collective trusts

         536,934,387        —         536,934,387        —   
      

     

     

        

     

     

        

     

     

        

     

     

     

    Total assets in the fair value hierarchy

       $ 972,478,827      $ 435,544,440      $ 536,934,387      $  —   
      

     

     

        

     

     

        

     

     

        

     

     

     

    Investments in the Stock Fund are stated at fair value based on the quoted market price on the last business day of the year for the Company’s common stock.

    Investments with original maturities of three months or less when purchased are considered interest-bearing cash. The fair values are based on observable market prices and, therefore, have been categorized in Level 1 of the fair value hierarchy.

    Investments in mutual funds are stated at fair value based on the quoted net asset value of shares held by the Plan on the last business day of the year.

    Investments under the self-directed brokerage account are stated at fair value based on the quoted market prices on the last business day of the year.

    Investments in common collective trusts are stated at fair value based on the published net asset value (“NAV”) per unit in the trust at year end. While participant transactions for common collective trusts take place daily, certain events, such as the premature termination of the contract by the Plan or the termination of the Plan, would require a redemption notice period of up to twelve months.

     

    7


    WATERS EMPLOYEE INVESTMENT PLAN

    Notes to Financial Statements

    December 31, 2023 and 2022

     

    The methods described above may produce a fair value that may not be indicative of the net realizable value or reflective of future fair value. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

    4 Related-Party Transactions

    Certain Plan investments are shares of mutual funds or collective trusts managed by an affiliate of Fidelity, a subsidiary of which is the trustee of the Plan and, therefore, these transactions qualify as party-in-interest transactions. Fees paid by the Plan to Fidelity or its affiliates for administrative services amounted to $486,979 for the year ended December 31, 2023. Transactions with respect to participant loans and the Stock Fund also qualify as party-in-interest transactions.

    The Plan has investments in shares of the Company’s common stock through the Stock Fund. During the year ended December 31, 2023, the Plan purchased units in the Stock Fund in the amount of $2,436,280; sold units in the Stock Fund in the amount of $8,106,333; and had net investment depreciation of $4,190,463, administrative expenses of $60,000 and interest and dividend income of $97,485. The total value of the Plan’s investment in the Stock Fund, which includes the Company’s common stock and related interest-bearing cash, was $72,611,195 and $82,434,226 at December 31, 2023 and 2022, respectively.

    Certain operating expenses and management fees are returned to the Plan based on revenue sharing arrangements with Fidelity. As Fidelity is the trustee and custodian of the Plan, these transactions qualify as party-in-interest transactions. The revenue sharing amounts received are recorded as other income in the statement of changes in net assets available for benefits. The Plan received $69,962 in revenue sharing payments for the year ended December 31, 2023, which was used to offset $486,979 of administrative expenses incurred by the Plan.

    5 Plan Amendment and Termination

    The Company expects to continue the Plan indefinitely; however, it has the right to modify, amend or terminate the Plan at any time subject to the provisions of the Code and ERISA. No such modification or amendment, however, shall have the effect of retroactively changing or depriving participants or beneficiaries of rights already accrued under the Plan. If the Plan is terminated, participants will remain 100% vested in their account balances.

    6 Tax Status

    The IRS has determined and informed the Company by a letter dated October 16, 2014, that the Plan and related trust are designed in accordance with applicable sections of the Code. Although the Plan has been amended since the effective date of the determination letter, the Plan administrator believes that the Plan is designed and is currently being operated in compliance with the applicable requirements of the Code. Therefore, no provision for income taxes has been included in the Plan’s financial statements.

    U.S. GAAP requires Plan management to evaluate uncertain tax positions taken by the Plan. The financial statement effects of a tax position are recognized when the position is more likely than not, based on the technical merits, to be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2023, there are no uncertain positions taken or expected to be taken. The Plan has recognized no interest or penalties related to uncertain tax positions. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

     

    8


    WATERS EMPLOYEE INVESTMENT PLAN

    Form 5500 – Schedule H, Part IV, Line 4i

    Schedule of Assets (Held at End of Year) as of December 31, 2023

     

    EIN:    04-3234558
    Plan Number 002

     

    (a)    (b)   (c)   (d)   (e)  
         Identity of issue, borrower,   Description of investment including maturity date,       Current  
          lessor or similar party   rate of interest, collateral, par, or maturity value   Cost   value  

    Waters Corporation Stock Fund

         

    *  

       Fidelity Management Trust Company (FMTC)   Interest-Bearing Cash   N/A   $ 1,942,963  

    *

       FMTC   Waters Corporation Common Stock   N/A     70,668,232  
            

     

     

     
      

    Total Waters Corporation Stock Fund

          72,611,195  

    Mutual funds

         
       Allspring   Special Mid Cap Value Fund – Class R6   N/A     6,588,555  
       American Funds   American Funds Washington Mutual Investors Fund - Class R6   N/A     28,122,787  
       American Century Funds   American Century Small Cap Value Fund – Class R6   N/A     16,614,431  
       MassMutual   MassMutual Mid Cap Growth Fund – Class I   N/A     20,872,944  
       Invesco   Invesco Developing Markets Fund – Class R6   N/A     12,228,550  

    *

       FMTC   Fidelity 500 Index Fund   N/A     147,741,564  

    *

       FMTC   Fidelity Extended Market Index Fund   N/A     48,552,233  

    *

       FMTC   Fidelity Investments Money Market Government Portfolio - Institutional Class   N/A     39,702,720  

    *

       FMTC   Fidelity U.S. Bond Index Fund   N/A     50,052,483  

    *

       FMTC   Fidelity Total International Index Fund   N/A     12,366,408  
            

     

     

     
      

    Total mutual funds

          382,842,675  

    Notes receivable from participants

       

    *

       Notes receivable from participants   Interest rates ranging from 3.25% to 8.50%; maturity dates through 2043   —      7,863,313  

    Self-directed brokerage assets

       

    *

       FMTC   Self-Directed BrokerageLink   N/A     49,461,154  

    Collective trusts

         

    *

       FMTC   Fidelity Freedom Blend 2005 Fund - Class R   N/A     1,715,707  

    *

       FMTC   Fidelity Freedom Blend 2010 Fund - Class R   N/A     1,393,894  

    *

       FMTC   Fidelity Freedom Blend 2015 Fund - Class R   N/A     4,167,948  

    *

       FMTC   Fidelity Freedom Blend 2020 Fund - Class R   N/A     33,439,150  

    *

       FMTC   Fidelity Freedom Blend 2025 Fund - Class R   N/A     47,349,696  

    *

       FMTC   Fidelity Freedom Blend 2030 Fund - Class R   N/A     90,539,642  

    *

       FMTC   Fidelity Freedom Blend 2035 Fund - Class R   N/A     44,061,649  

    *

       FMTC   Fidelity Freedom Blend 2040 Fund - Class R   N/A     53,314,864  

    *

       FMTC   Fidelity Freedom Blend 2045 Fund - Class R   N/A     31,817,155  

    *

       FMTC   Fidelity Freedom Blend 2050 Fund - Class R   N/A     30,489,679  

    *

       FMTC   Fidelity Freedom Blend 2055 Fund - Class R   N/A     19,495,113  

    *

       FMTC   Fidelity Freedom Blend 2060 Fund - Class R   N/A     10,173,853  

    *

       FMTC   Fidelity Freedom Blend 2065 Fund - Class R   N/A     3,677,044  

    *

       FMTC   Fidelity Freedom Blend Income Fund - Class R   N/A     5,054,342  

    *

       FMTC   Fidelity Diversified International Commingled Pool   N/A     33,092,044  

    *

       FMTC   Fidelity Managed Income Portfolio Class II   N/A     19,330,787  

    *

       FMTC   Fidelity Growth Company Commingled Pool   N/A     191,252,301  
            

     

     

     
      

    Total collective trusts

          620,364,868  
          

     

     

     
      

    Total investments

        $ 1,133,143,205  
            

     

     

     

     

    *

    Party-in-interest

     

    9

    Get the next $WAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    2/10/2026$360.00In-line
    Evercore ISI
    2/10/2026$425.00Buy
    Citigroup
    2/10/2026$400.00Overweight
    Barclays
    1/6/2026$440.00Buy
    Guggenheim
    1/5/2026Outperform
    William Blair
    12/10/2025$480.00Peer Perform → Outperform
    Wolfe Research
    12/2/2025$423.00Equal-Weight
    Morgan Stanley
    10/8/2025$390.00Buy
    Rothschild & Co Redburn
    More analyst ratings

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation

    FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business and the combination of the business with Waters Corporation (NYSE:WAT).  In connection with the transaction, BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD common stock that they held as of the close of business on February 5, 2026, the record date for the spin-off, with cash in lieu of any fractional shares of Waters common stock, and BD received $4 billion of cash. As of the closing of the transaction, BD's share

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

    Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in

    2/9/26 6:30:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Waters Division Carpio Robert L Iii covered exercise/tax liability with 38 shares, decreasing direct ownership by 1% to 2,618 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    2/6/26 7:34:54 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP TA Instruments Division Bennett Jianqing was granted 1,385 shares and covered exercise/tax liability with 43 shares, increasing direct ownership by 27% to 6,258 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    2/6/26 7:33:43 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP & Chief Financial Officer Chaubal Amol was granted 1,884 shares and covered exercise/tax liability with 58 shares, increasing direct ownership by 35% to 7,050 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    2/6/26 7:32:21 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    SEC Filings

    View All

    Waters Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WATERS CORP /DE/ (0001000697) (Filer)

    2/9/26 4:16:29 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - WATERS CORP /DE/ (0001000697) (Filer)

    2/9/26 7:00:30 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - WATERS CORP /DE/ (0001000697) (Filer)

    1/27/26 4:15:15 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Waters with a new price target

    Evercore ISI resumed coverage of Waters with a rating of In-line and set a new price target of $360.00

    2/10/26 8:10:12 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Barclays resumed coverage on Waters with a new price target

    Barclays resumed coverage of Waters with a rating of Overweight and set a new price target of $400.00

    2/10/26 8:03:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Citigroup resumed coverage on Waters with a new price target

    Citigroup resumed coverage of Waters with a rating of Buy and set a new price target of $425.00

    2/10/26 8:03:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

    Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in

    2/9/26 6:30:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

    Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters. 

    1/27/26 9:25:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Jan. 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2025 financial results conference call on Thursday, February 12th, 2026 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 12, 2026, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety o

    1/20/26 1:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials